Guidance, NICE advice and quality standards in development | Guidance

Showing 11 to 20 of 382

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Alpelisib with olaparib for treating BRCA wild-type platinum-refractory or -resistant ovarian, fallopian tube or primary peritoneal cancer after 1 to 3 previous treatments [TSID11830] [ID6247]	Technology appraisal guidance	TBC
ALXN1840 for treating Wilson disease [ID6422]	Technology appraisal guidance	TBC
Alzheimer's disease (early) - gantenerumab [ID6142]	Technology appraisal guidance	TBC
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]	Technology appraisal guidance	23 October 2025
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6256]	Technology appraisal guidance	23 October 2025
Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]	Technology appraisal guidance	TBC
Apraglutide for treating short bowel syndrome [ID6533]	Technology appraisal guidance	TBC
Arimoclomol for treating Niemann-Pick disease Type C [ID1312]	Highly specialised technology	TBC
Artificial intelligence (AI) technologies to aid opportunistic detection of vertebral fragility fractures: Early Value Assessment	Health technology evaluation	10 October 2025
Artificial Intelligence assisted Echocardiography to support diagnosis of heart failure: Early Value Assessment	Health technology evaluation	19 May 2026